Printer Friendly

DISEASE DETECTION INTERNATIONAL INC. HAS SEVEN-MINUTE AIDS TEST APPROVED IN MEXICO

 DISEASE DETECTION INTERNATIONAL INC. HAS SEVEN-MINUTE
 AIDS TEST APPROVED IN MEXICO
 SeroCard (R) HIV-I Test Uses Whole Blood Sample From Simple
 Finger Stick, Results Compare with Three-Hour Lab Test
 IRVINE, Calif., Aug. 19 /PRNewswire/ -- Disease Detection International, Inc. (NASDAQ: DDII), announced today that the company's seven-minute, whole blood, AIDS test has been approved for sale and manufacturing in Mexico by the Secretary of Health. The company's patented, credit card-sized device, SeroCard(R) HIV-I, was designed for use in the physician's office, emergency centers, surgery departments, penal institutions and other settings where an immediate, reliable answer is desirable.
 In studies performed by the Federal Center for Blood Transfusion in Mexico City, the SeroCard HIV-I test was found to have a sensitivity of 100 percent and a specificity of 99.4 percent when compared to conventional three-hour tests and confirmatory western blot analysis. The positive predictive value (PPV) was 99.2 percent and the Negative Predictive Value (NPV) was 100 percent. The company received notice of the approval through its manufacturing partner in Mexico, Joseph Vilella y Asociados International, S.A. de C.V. ("JV&A"). JV&A's Fernando Mejia coordinated the application in Mexico City. Government officials were complimentary of the quality of the submission and the test performance which resulted in the approval being granted 30 days from the date of application. JV&A will manufacture test kits in Mexico for both DDI and Trinity Biotech, plc., of Dublin, Ireland, DDI's exclusive worldwide licensee and major shareholder. The Mexican manufacturing facility, believed to be the first in Mexico to manufacture rapid AIDS tests, was founded by Joseph Vilella and Frank Chabza, experienced manufacturing engineers, and Mejia, a chemical engineer.
 In making the announcement, DDI's President and Chief Executive Officer H. Thad Morris stated that "the approval of our product for sale in Mexico is a significant event for the company, in that Mexico marks the fourth successful international study (previous studies were conducted in Sweden, Thailand and Puerto Rico) on the SeroCard HIV-I test. Each study has proven that we can provide a reliable result in just minutes without the expense, expertise and trauma associated with drawing a blood sample for conventional tests which require a serum or plasma sample. It is our belief that the patented SeroCard format will pave the way for emergency testing, epidemiological studies and screening, particularly in third world countries where the available expertise and expensive equipment needed to process samples for testing is limited." Mexico has also approved the export of the SeroCard HIV test to 17 countries.
 Dr. Anthony C. Nicholls, Trinity Biotech's president and chief executive officer, says, "This is an important event which opens significant markets for us, reinforcing the value of DDI's technology and management's ability to transfer the manufacturing to other sites." Nicholls also commented that the sensitivity and specificity results reinforce Trinity's belief that its adaptation of the DDI technology to saliva testing ("SalivaCard HIV-I") will yield successful clinical results in the near future.
 Both executives share the belief that DDI's SeroCard HIV-I and Trinity's current adaptation of the SeroCard HIV-I to saliva testing, ("SalivaCard HIV-I") will play important roles in reducing the risks and costs of infectious disease diagnostic testing. In major healthcare institutions in the United States, the costs to prepare a conventional serum sample for testing range from $6-$18. The SeroCard HIV-I test, which uses whole blood from a simple finger stick, can save up to 85 percent. These up-front savings, considering the tens of millions of samples to be tested in this pandemic, are very significant.
 Disease Detection International Inc. has previously received United States Food and Drug Administration (FDA) approval for three similar SeroCard tests, which use whole blood to detect antibodies to Rubella Virus, Cytomegalovirus (CMV) and Herpes Simplex Virus (HSV). The company is preparing documents to seek FDA approval for the SeroCard HIV test to be manufactured and marketed in the United States.
 Disease Detection International Inc. develops, manufactures, and markets rapid tests for the chemical and immunological detection of infectious and sexually transmitted diseases.
 -0- 8/19/92
 /CONTACT: H. Thad Morris, president and CEO of Disease Detection, 714-457-1787/
 (DDII) CO: Disease Detection International Inc. ST: California IN: MTC SU: PDT


AL -- LA026 -- 1411 08/19/92 14:45 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 19, 1992
Words:711
Previous Article:BANKAMERICA'S $350 MILLION 6 PERCENT SENIOR NOTES RATED 'AA-' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:METHODIST HOSPITAL OF INDIANA UPGRADED TO 'Aa' BY MOODY'S 43rd 'Aa' RATED HEALTHCARE INSTITUTION
Topics:


Related Articles
MUREX ANNOUNCES NEW AIDS TEST AVAILABLE; YIELDS ACCURATE RESULTS IN 10 MINUTES
DISEASE DETECTION INTERNATIONAL INC. ANNOUNCES FIRST QUARTER 1992 PROFITS AND 1991 YEAR-END LOSS REDUCTION
DISEASE DETECTION INTERNATIONAL FILES 'IND' APPLICATION WITH FDA SEEKING APPROVAL TO BEGIN FORMAL CLINICAL STUDIES FOR SEVEN-MINUTE AIDS TEST
DISEASE DETECTION INTERNATIONAL INC. COMPLETES $4.5-MILLION FINANCIAL RESTRUCTURING
DISEASE DETECTION INTERNATIONAL TO COMMENCE U.S.A. CLINICAL TRIALS OF SEVEN-MINUTE, SEROCARD(R) HIV-1, AIDS TEST UNDER FDA 'IND' SUBMISSION
DISEASE DETECTION INTERNATIONAL REPORTS RECORD REVENUES AND PROFITS FOR FISCAL 1992 AND SIGNIFICANT FORECASTS FOR 1993 AND BEYOND
DISEASE DETECTION INTERNATIONAL INC.COMPLETES $3.0 MILLION PRIVATE PLACEMENT
DISEASE DETECTION INTERNATIONAL INC. (DDI) ANNOUNCES BRASILIAN APPROVAL TO SELL RAPID, ON-SITE, AIDS TEST
ARGENTINA MINISTRY OF HEALTH APPROVES DISEASE DETECTION INTERNATIONAL'S SEVEN-MINUTE, WHOLE BLOOD AIDS TEST FOR USE IN NATIONAL PROGRAM
DISEASE DETECTION INTERNATIONAL TO SUPPLY 1.2 MILLION TESTS IN BRASILIAN FEDERAL AIDS PROGRAM FOR THE STATE OF SAO PAULO, BRASIL

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters